Azenta, Inc. - Common Stock (AZTA)
37.14
+1.59 (4.47%)
NASDAQ · Last Trade: Nov 3rd, 10:53 AM EST
News & Press Releases
3 Reasons to sell AZTA and 1 stock to buy instead
What a fantastic six months it’s been for Azenta. Shares of the company have skyrocketed 46.2%, hitting $35.57. This was partly due to its solid quarterly re...
Via StockStory · November 2, 2026
3 small-cap stocks we find risky
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via StockStory · October 30, 2026
Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · October 25, 2026
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...
Via StockStory · October 19, 2026
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...
Via StockStory · October 16, 2026
Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NY...
Via StockStory · October 15, 2026
2 Volatile Stocks with Promising Prospects and 1 We Ignore
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be...
Via StockStory · October 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · October 6, 2026
Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input...
Via StockStory · October 5, 2026
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 30, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 29, 2026
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · September 26, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 22, 2026
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 21, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 15, 2026
Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta...
Via StockStory · September 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 8, 2026
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 7, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 1, 2026
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Via StockStory · September 1, 2026
Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and...
Via StockStory · August 25, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 25, 2026
Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group
Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft...
Via StockStory · August 25, 2026
Why Azenta (AZTA) Stock Is Down Today
What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, t...
Via StockStory · August 24, 2026
1 Momentum Stock for Long-Term Investors and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
Via StockStory · August 19, 2026